FlexGen of the Netherlands said last week that China's BGI and Leiden University Medical Center will use its target enrichment technology to validate variants for the Genome of the Netherlands, or GoNL, project.
The researchers will use the platform to validate a set of variants found in trio samples from the GoNL project. Launched in 2010, the project aims to sequence the genomes of about 250 Dutch parent-child trios. The sequencing is performed at BGI's Hong Kong facility.
FlexGen, located in the Leiden Bio Science Park, was founded in 2004 as a spinoff from Leiden University Medical Center and Dutch Space. The company offers FleXelect custom target enrichment kits.